Biopharmaceutical leaders today are charting a course through unprecedented regulatory uncertainty and market turbulence. From shifting FDA and EMA approva...
New formulations simplify microbial bioprocessing, helping innovators scale plasmid DNA and protein production with confidence Thermo Fisher Scien...
Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announc...
Vanda Pharmaceuticals Inc. announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ims...
Anova launches a free AI-enabled patient matching solution that uses proprietary algorithms to connect patients to 200,000+ open clinical trials with...
Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in Gout Acquisition expected to be highly accretive to...
Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (n...
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the si...
SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, announced the launch of two s...
SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic...
Convergen, a biotech company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, announced th...
Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Co...
-Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolesc...
Incyte announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INCA033989, a first-in-class muta...
© 2026 Biopharma Boardroom. All Rights Reserved.
